Supplementary Figure S3 from A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer | Synapse
June 3, 2024Open Access
Supplementary Figure S3 from A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer
Key Points
Key points are not available for this paper at this time.
Abstract
Figure S3: Mean baseline cortisol calculated in twenty (20) patients at day 1 and day 28